Mullinsstilling7165

SDMT had a balanced sensitivity, while CVLT-II and BVMT-R had higher specificities than sensitivities at detecting CI. More specifically, BVMT-R showed 100% specificity for all CI definitions. Raw cut-off scores for BICAMS tests are also provided within the manuscript, along with the diagnostic calculations.

In this study, we confirmed that BICAMS is a good screening tool for CI and that simple cut-offs can be used in the everyday neurological practice.

In this study, we confirmed that BICAMS is a good screening tool for CI and that simple cut-offs can be used in the everyday neurological practice.We describe a method to assign weights to genotype combinations at the Amelogenin locus. It is a typical practise in forensic laboratories that once the weight exceeds a threshold (such as 99 %), then they can be considered to be resolved enough to interpret (for example to load onto a database). We found that unless an individual is a clear major (or minor) contributor, the genotype weights do not typically exceed 99 % for any genotype. LRs have not been traditionally assigned for the Amelogenin locus and are small compared to an LR assigned for a modern day STR multiplex where, for a more discriminatory locus, the per locus LR for a resolved contributor could be in the order of tens or hundreds. The method described uses per contributor template values for a previously interpreted profile. The discrimination power is restricted, with a maximum possible LR of 2 for a fully resolved genotype, due to the limited number of alleles and hence genotypes and assuming equal proportions of genders in the population. However, it has a good power to exclude when the component is well resolved and non-concordant with a POI.

The determination of output factors in small field dosimetry is a crucial point, especially when implementing stereotactic radiotherapy (SRT). Herein, a working group of the French medical physicist society (SFPM) was created to collect small field output factors. The objective was to gather and disseminate information on small field output factors based on different detectors for various clinical SRT equipment and measurement configurations.

Participants were surveyed for information about their SRT equipment, including the type of linear particle accelerator (linac), collimator settings, measurement conditions for the output factors and the detectors used. Participants had to report both the ratio of detector readings and the correction factors applied as described in the IAEA TRS-483 code of practice for nominal field sizes smaller or equal to 3cm. Mean field output factors and their associated standard deviations were calculated when data from at least 3 linacs were available.

23 centres were enrolled in the project. Standard deviations of the mean field output factors were systematically smaller than 1.5% for field sizes larger or equal to 1cm and reached 5% for the smallest field size (0.5cm). Selleckchem Dexketoprofen trometamol Deviations with published data were smaller than 2% except for the 0.5cm circular fixed aperture collimator of the CyberKnife where it reached 3.5%.

These field output factor values obtained via a large multicentre study can be considered as an external cross verification for any radiotherapy centre starting a SRT program and should help minimize systematic errors when determining small field output factors.

These field output factor values obtained via a large multicentre study can be considered as an external cross verification for any radiotherapy centre starting a SRT program and should help minimize systematic errors when determining small field output factors.

The aim of this work was to develop a computational scheme for the correction of the LET dependence on the MOSFET response in water phantom dose measurements for a spread-out Bragg peak (SOBP) proton beam.

The LET dependence of MOSFET was attributed to the stopping power ratio of SiO

to H

O and to the fractional hole yield in the SiO

layer. Using literature values for the stopping powers of the continuous slowing down approximation and measured fractional hole yields vs. electric field and LET, formulas were derived for the computation of a dose-weighted correction factor of a SOBP beam.

Dose-weighted correction factors were computed for a clinical 190-MeV proton SOBP beam in a high-density polyethylene phantom. By applying correction factors to the SOBP beam, which consisted of weighted monoenergetic Bragg peaks, the MOSFET outputs were predicted and agreed well with the measured MOSFET responses.

By applying LET dependent correction factors to MOSFET data, quality assurance of dose verification based on MOSFET measurements becomes possible for proton therapy.

By applying LET dependent correction factors to MOSFET data, quality assurance of dose verification based on MOSFET measurements becomes possible for proton therapy.In recent years, a growing interest has been shown in the implementation of software dedicated to the skin dose calculation, since the Fluoroscopically Guided Interventions are expanding in various medical areas. In this regard, a review article recently published by Malchair et al. (2020) is of great importance as it provides the reader with useful references to the software currently available to estimate the patient's skin dose. Despite the usefulness of collecting and summarizing in one paper the different software solutions, a few critical issues have emerged related to some parameters and configurations used in the estimation; additional details concerning patient's size and position can be added to the information cited by the authors, giving greater robustness to the software calculation. Furthermore, software results cited in the benchmarking without reference cause a lack of solid information. Our suggestion is to adopt the given criteria to evaluate every available software solutions thus helping the eventual user to analyse the tool before adopting it.

The objectives of the study were to establish a procedure for in vivo film-based dosimetry for intraoperative radiotherapy (IORT), evaluate the typical doses delivered to organs at risk, and verify the dose prescription.

In vivo dose measurements were studied using XR-RV3 radiochromic films in 30 patients with breast cancer undergoing IORT using the Axxent® device (Xoft Inc.). The stability of the radiochromic films in the energy ranges used was verified by taking measurements at different depths. The stability of the scanner response was tested, and 5 different calibration curves were constructed for different beam qualities. Six pieces of film were placed in each of the 30 patients. All the pieces were correctly sterilized and checked to ensure that the process did not affect the outcome. All calibration and dose measurements were analyzed using the Radiochromic.com software application.

The doses were measured for 30 patients. The doses in contact with the applicator (prescription zone) were 19.8±0.9Gy.